

# Klaus Lieb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6993409/publications.pdf>

Version: 2024-02-01

184  
papers

12,501  
citations

20817

60  
h-index

30087

103  
g-index

218  
all docs

218  
docs citations

218  
times ranked

12304  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Group Intervention to Promote Resilience in Nursing Professionals: A Randomised Controlled Trial. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 649.	2.6	10
2	Resilience Interventions Conducted in Western and Eastern Countriesâ€”A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6913.	2.6	4
3	Physiciansâ€™ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey. <i>BMJ Open</i> , 2022, 12, e055963.	1.9	2
4	Plain language summaries: A systematic review of theory, guidelines and empirical research. <i>PLoS ONE</i> , 2022, 17, e0268789.	2.5	20
5	Resilience beyond reductionism: ethical and social dimensions of an emerging concept in the neurosciences. <i>Medicine, Health Care and Philosophy</i> , 2021, 24, 55-63.	1.8	7
6	Differential impact of COVID-related lockdown on mental health in Germany. <i>World Psychiatry</i> , 2021, 20, 140-141.	10.4	78
7	Is pharmacotherapy useful for treating personality disorders?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 393-395.	1.8	6
8	Mental health and psychosocial support strategies in highly contagious emerging disease outbreaks of substantial public concern: A systematic scoping review. <i>PLoS ONE</i> , 2021, 16, e0244748.	2.5	27
9	Association between psychological resilience and changes in mental distress during the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2021, 282, 381-385.	4.1	105
10	Association of Innate and Acquired Aerobic Capacity With Resilience in Healthy Adults: Protocol for a Randomized Controlled Trial of an 8-Week Web-Based Physical Exercise Intervention. <i>JMIR Research Protocols</i> , 2021, 10, e29712.	1.0	4
11	Individual participant data systematic reviews with meta-analyses of psychotherapies for borderline personality disorder. <i>BMJ Open</i> , 2021, 11, e047416.	1.9	7
12	Early onset of depression and treatment outcome in patients with major depressive disorder. <i>Journal of Psychiatric Research</i> , 2021, 139, 150-158.	3.1	22
13	The Frequent Stressor and Mental Health Monitoring-Paradigm: A Proposal for the Operationalization and Measurement of Resilience and the Identification of Resilience Processes in Longitudinal Observational Studies. <i>Frontiers in Psychology</i> , 2021, 12, 710493.	2.1	33
14	Influence of gender on cytokine induced depression and treatment. <i>Journal of Affective Disorders</i> , 2021, 292, 766-772.	4.1	3
15	Longitudinal CSF proteome profiling in mice to uncover the acute and sustained mechanisms of action of rapid acting antidepressant (2R,6R)-hydroxynorketamine (HNK). <i>Neurobiology of Stress</i> , 2021, 15, 100404.	4.0	8
16	Borderline personality disorder. <i>Lancet, The</i> , 2021, 398, 1528-1540.	13.7	113
17	Surprise: Unexpected Action Execution and Unexpected Inhibition Recruit the Same Fronto-Basal-Ganglia Network. <i>Journal of Neuroscience</i> , 2021, 41, 2447-2456.	3.6	12
18	Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 62-66.	1.4	8

#	ARTICLE	IF	CITATIONS
19	Mental health in refugees and asylum seekers (MEHIRA): study design and methodology of a prospective multicentre randomized controlled trial investigating the effects of a stepped and collaborative care model. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 95-106.	3.2	45
20	Higher BDNF plasma levels are associated with a normalization of memory dysfunctions during an antidepressant treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 183-193.	3.2	10
21	Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016. <i>BMJ Open</i> , 2020, 10, e037395.	1.9	13
22	Discrepancies from registered protocols and spin occurred frequently in randomized psychotherapy trials – A meta-epidemiologic study. <i>Journal of Clinical Epidemiology</i> , 2020, 128, 49-56.	5.0	14
23	Psychological therapies for people with borderline personality disorder. <i>The Cochrane Library</i> , 2020, 2020, CD012955.	2.8	158
24	Non-Pharmacologic Multicomponent Interventions Preventing Delirium in Hospitalized People. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1864-1871.	2.6	44
25	Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies. <i>Current Psychiatry Reports</i> , 2020, 22, 37.	4.5	48
26	Effects of age on depressive symptomatology and response to antidepressant treatment in patients with major depressive disorder aged 18 to 65 years. <i>Comprehensive Psychiatry</i> , 2020, 99, 152170.	3.1	12
27	Impact of physicians' participation in non-interventional post-marketing studies on their prescription habits: A retrospective 2-armed cohort study in Germany. <i>PLoS Medicine</i> , 2020, 17, e1003151.	8.4	5
28	Teaching Conflicts of Interest and Shared Decision-Making to Improve Risk Communication: a Randomized Controlled Trial. <i>Journal of General Internal Medicine</i> , 2020, 35, 473-480.	2.6	17
29	Bouncing Back from the Burden of Dementia. <i>GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry</i> , 2020, 33, 170-181.	0.5	10
30	Assessment of Microstressors in Adults: Questionnaire Development and Ecological Validation of the Mainz Inventory of Microstressors. <i>JMIR Mental Health</i> , 2020, 7, e14566.	3.3	34
31	Psychomorbidity, Resilience, and Exacerbating and Protective Factors During the SARS-CoV-2 Pandemic. <i>Deutsches Ärzteblatt International</i> , 2020, 117, 625-630.	0.9	58
32	Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response. <i>Journal of Affective Disorders</i> , 2019, 256, 524-531.	4.1	38
33	Understanding and Predicting Antidepressant Response: Using Animal Models to Move Toward Precision Psychiatry. <i>Frontiers in Psychiatry</i> , 2018, 9, 512.	2.6	14
34	BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response. <i>Frontiers in Psychiatry</i> , 2018, 9, 511.	2.6	35
35	Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2018, 13, 37.	2.2	25
36	Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder. <i>PLoS ONE</i> , 2018, 13, e0194574.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Construct Validity and Population-Based Norms of the German Brief Resilience Scale (BRS). <i>European Journal of Health Psychology</i> , 2018, 25, 107-117.	0.6	47
38	Population-based validation of a German version of the Brief Resilience Scale. <i>PLoS ONE</i> , 2018, 13, e0192761.	2.5	138
39	Individualized Web-Based Exercise for the Treatment of Depression: Randomized Controlled Trial. <i>JMIR Mental Health</i> , 2018, 5, e10698.	3.3	28
40	Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials. <i>JMIR Research Protocols</i> , 2018, 7, e106.	1.0	17
41	Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial. <i>European Neuropsychopharmacology</i> , 2017, 27, 248-260.	0.7	58
42	Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 711-721.	3.2	18
43	A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depressive Disorders. <i>Journal of Affective Disorders</i> , 2017, 221, 184-191.	4.1	6
44	The resilience framework as a strategy to combat stress-related disorders. <i>Nature Human Behaviour</i> , 2017, 1, 784-790.	12.0	420
45	Neural Architecture of Selective Stopping Strategies: Distinct Brain Activity Patterns Are Associated with Attentional Capture But Not with Outright Stopping. <i>Journal of Neuroscience</i> , 2017, 37, 9785-9794.	3.6	25
46	Industrie-Einflüsse auf die Arzneimittelversorgung – mehr Unabhängigkeit ist möglich. <i>Public Health Forum</i> , 2017, 25, 215-217.	0.2	0
47	Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2017, 94, 96-106.	3.1	62
48	Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. <i>Addiction Biology</i> , 2017, 22, 1449-1458.	2.6	7
49	Data-driven analysis of simultaneous EEG/fMRI reveals neurophysiological phenotypes of impulse control. <i>Human Brain Mapping</i> , 2016, 37, 3114-3136.	3.6	16
50	Conflicts of interest and spin in reviews of psychological therapies: a systematic review. <i>BMJ Open</i> , 2016, 6, e010606.	1.9	40
51	Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial. <i>European Neuropsychopharmacology</i> , 2016, 26, 705-716.	0.7	38
52	Cannabis for Cognitive Enhancement as a New Coping Strategy? Results From a Survey of Students at Four Universities in Germany. <i>Substance Use and Misuse</i> , 2016, 51, 1856-1862.	1.4	11
53	Molecular cause and functional impact of altered synaptic lipid signaling due to a <i>prg1</i> gene <i>SNP</i> . <i>EMBO Molecular Medicine</i> , 2016, 8, 25-38.	6.9	40
54	Dissociable attentional and inhibitory networks of dorsal and ventral areas of the right inferior frontal cortex: a combined task-specific and coordinate-based meta-analytic fMRI study. <i>Brain Structure and Function</i> , 2016, 221, 1635-1651.	2.3	67

#	ARTICLE	IF	CITATIONS
55	The Amount of Mitochondrial DNA in Blood Reflects the Course of a Depressive Episode. <i>Biological Psychiatry</i> , 2016, 80, e41-e42.	1.3	24
56	The Use of Caffeinated Substances by Surgeons for Cognitive Enhancement. <i>Annals of Surgery</i> , 2015, 261, 1091-1095.	4.2	37
57	Women with borderline personality disorder do not show altered BOLD responses during response inhibition. <i>Psychiatry Research - Neuroimaging</i> , 2015, 234, 378-389.	1.8	26
58	Lack of Breastfeeding: A Potential Risk Factor in the Multifactorial Genesis of Borderline Personality Disorder and Impaired Maternal Bonding. <i>Journal of Personality Disorders</i> , 2015, 29, 610-626.	1.4	25
59	Declaration and Handling of Conflicts of Interest in Guidelines. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2015, 112, 445-51.	0.9	8
60	Frontal Dysfunctions of Impulse Control – A Systematic Review in Borderline Personality Disorder and Attention-Deficit/Hyperactivity Disorder. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 698.	2.0	119
61	Data-driven analysis of simultaneous EEG/fMRI using an ICA approach. <i>Frontiers in Neuroscience</i> , 2014, 8, 175.	2.8	9
62	Behavioral components of impulsivity.. <i>Journal of Experimental Psychology: General</i> , 2014, 143, 850-886.	2.1	205
63	Age-related increases in stroop interference: Delineation of general slowing based on behavioral and white matter analyses. <i>Human Brain Mapping</i> , 2014, 35, 2448-2458.	3.6	42
64	Borderline Personality Disorder and Comorbid Addiction. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2014, 111, 280-6.	0.9	64
65	Analysis of genome-wide significant bipolar disorder genes in borderline personality disorder. <i>Psychiatric Genetics</i> , 2014, 24, 262-265.	1.1	26
66	Responding to the Treatment Challenge of Patients with Severe BPD: Results of Three Pilot Studies of Inpatient Schema Therapy. <i>Behavioural and Cognitive Psychotherapy</i> , 2014, 42, 355-367.	1.2	38
67	Association between dopa decarboxylase gene variants and borderline personality disorder. <i>Psychiatry Research</i> , 2014, 219, 693-695.	3.3	3
68	A 48-year-old woman with panic attacks. <i>Lancet, The</i> , 2014, 384, 280.	13.7	4
69	Contact between Doctors and the Pharmaceutical Industry, Their Perceptions, and the Effects on Prescribing Habits. <i>PLoS ONE</i> , 2014, 9, e110130.	2.5	97
70	The ‘DGPPN-Cohort’ a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 695-701.	3.2	17
71	Effects of Shame Induction in Borderline Personality Disorder. <i>Cognitive Therapy and Research</i> , 2013, 37, 1160-1168.	1.9	29
72	Emotional modulation of motor response inhibition in women with borderline personality disorder: an fMRI study. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 164-172.	2.4	60

#	ARTICLE	IF	CITATIONS
73	Associations between Physical and Cognitive Doping – A Cross-Sectional Study in 2.997 Triathletes. PLoS ONE, 2013, 8, e78702.	2.5	54
74	Medical Students' Attitudes to and Contact With the Pharmaceutical Industry. Deutsches Ärzteblatt International, 2013, 110, 584-90.	0.9	24
75	Effects of Sleep Deprivation on Nocturnal Cytokine Concentrations in Depressed Patients and Healthy Control Subjects. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 354-366.	1.8	33
76	Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. International Clinical Psychopharmacology, 2012, 27, 61-68.	1.7	48
77	Escitalopram for the Prevention of Peginterferon- $\alpha$ 2a-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease. Annals of Internal Medicine, 2012, 157, 94.	3.9	59
78	Small amygdala – high aggression? The role of the amygdala in modulating aggression in healthy subjects. World Journal of Biological Psychiatry, 2012, 13, 75-81.	2.6	60
79	Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology, 2012, 62, 264-269.	4.1	62
80	What Users Think about the Differences between Caffeine and Illicit/Prescription Stimulants for Cognitive Enhancement. PLoS ONE, 2012, 7, e40047.	2.5	67
81	Neural correlates of interference inhibition, action withholding and action cancellation in adult ADHD. Psychiatry Research - Neuroimaging, 2012, 202, 132-141.	1.8	66
82	Early life stress stimulates hippocampal reelin gene expression in a sex-specific manner: Evidence for corticosterone-mediated action. Hippocampus, 2012, 22, 409-420.	1.9	39
83	Comparison of different strategies to decrease negative affect and increase positive affect in women with borderline personality disorder. Behaviour Research and Therapy, 2011, 49, 68-73.	3.1	28
84	The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 415-420.	4.8	67
85	Dopamine D2/D3 receptor availability and venturesomeness. Psychiatry Research - Neuroimaging, 2011, 193, 80-84.	1.8	11
86	State dependent posterior hippocampal volume increases in patients with major depressive disorder. Journal of Affective Disorders, 2011, 135, 405-409.	4.1	37
87	Impulsiveness and Venturesomeness in German Smokers. Nicotine and Tobacco Research, 2011, 13, 714-721.	2.6	11
88	Standardized Rater Training for the Hamilton Depression Rating Scale (HAM-D-17) and the Inventory of Depressive Symptoms (IDS-C30). Psychopathology, 2011, 44, 68-70.	1.5	24
89	Reliability of Three Alternate Forms of the Trail Making Tests A and B. Archives of Clinical Neuropsychology, 2011, 26, 314-321.	0.5	107
90	A Survey of German Physicians in Private Practice About Contacts With Pharmaceutical Sales Representatives. Deutsches Ärzteblatt International, 2010, 107, 392-8.	0.9	63

#	ARTICLE	IF	CITATIONS
91	Impulsivity in Borderline Personality Disorder: Impairment in Self-Report Measures, but Not Behavioral Inhibition. <i>Psychopathology</i> , 2010, 43, 180-188.	1.5	82
92	Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: study protocol of a randomized controlled multicentre trial. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2010, 2, 203-212.	1.7	50
93	Association analysis between gene variants of the tyrosine hydroxylase and the serotonin transporter in borderline personality disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 45-58.	2.6	10
94	Group Therapy Module to Enhance Self-Esteem in Patients with Borderline Personality Disorder: A Pilot Study. <i>International Journal of Group Psychotherapy</i> , 2010, 60, 373-387.	0.6	13
95	Reduced interhemispheric structural connectivity between anterior cingulate cortices in borderline personality disorder. <i>Psychiatry Research - Neuroimaging</i> , 2010, 181, 151-154.	1.8	43
96	Neurochemical alterations in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 372-381.	2.6	23
97	Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. <i>British Journal of Psychiatry</i> , 2010, 196, 4-12.	2.8	334
98	The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2010, 107, 279-85.	0.9	96
99	The Financing of Drug Trials by Pharmaceutical Companies and Its Consequences. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2010, 107, 295-301.	0.9	71
100	Gender Differences in Axis I and Axis II Comorbidity in Patients with Borderline Personality Disorder. <i>Psychopathology</i> , 2009, 42, 257-263.	1.5	82
101	Extraction of prefronto-amygdalar pathways by combining probability maps. <i>Psychiatry Research - Neuroimaging</i> , 2009, 174, 217-222.	1.8	52
102	The 5-HTTLPR Polymorphism modulates the association of serious life events (SLE) and impulsivity in patients with Borderline Personality Disorder. <i>Journal of Psychiatric Research</i> , 2009, 43, 1067-1072.	3.1	65
103	Time course of response to antidepressants: Predictive value of early improvement and effect of additional psychotherapy. <i>Journal of Affective Disorders</i> , 2009, 114, 243-253.	4.1	69
104	Association analysis of serotonin receptor 1B (HTR1B) and brain-derived neurotrophic factor gene polymorphisms in borderline personality disorder. <i>Journal of Neural Transmission</i> , 2009, 116, 1185-1188.	2.8	18
105	Borderline typical symptoms in adult patients with attention deficit/hyperactivity disorder. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2009, 1, 11-18.	1.7	46
106	SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnesic mild cognitive impairment from healthy aging. <i>NeuroImage</i> , 2009, 44, 43-50.	4.2	117
107	Emotional Reactions to Standardized Stimuli in Women With Borderline Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , 2009, 197, 808-815.	1.0	56
108	Regulation of prostaglandin E <sub>2</sub> synthase expression in activated primary rat microglia: Evidence for uncoupled regulation of mPGES <sub>1</sub> and COX <sub>2</sub> . <i>Glia</i> , 2008, 56, 844-855.	4.9	73

#	ARTICLE	IF	CITATIONS
109	Association analysis of SCN9A gene variants with borderline personality disorder. <i>Journal of Psychiatric Research</i> , 2008, 43, 155-163.	3.1	13
110	Time course of anger and other emotions in women with borderline personality disorder: A preliminary study. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2008, 39, 391-402.	1.2	51
111	Predictors of dropout from inpatient dialectical behavior therapy among women with borderline personality disorder. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2008, 39, 497-503.	1.2	76
112	Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. <i>British Journal of Psychiatry</i> , 2008, 192, 118-123.	2.8	173
113	State affective instability in borderline personality disorder assessed by ambulatory monitoring. <i>Psychological Medicine</i> , 2007, 37, 961-970.	4.5	197
114	The Impact of Posttraumatic Stress Disorder on Dysfunctional Implicit and Explicit Emotions Among Women With Borderline Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 537-539.	1.0	35
115	An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Depressed Inpatients: Acute and Long-Term Results. <i>American Journal of Psychiatry</i> , 2007, 164, 768-777.	7.2	139
116	Elevated pain thresholds correlate with dissociation and aversive arousal in patients with borderline personality disorder. <i>Psychiatry Research</i> , 2007, 149, 291-296.	3.3	144
117	Measuring shame and guilt by self-report questionnaires: A validation study. <i>Psychiatry Research</i> , 2007, 150, 313-325.	3.3	96
118	Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. <i>NeuroImage</i> , 2007, 35, 738-747.	4.2	91
119	Shame and Implicit Self-Concept in Women With Borderline Personality Disorder. <i>American Journal of Psychiatry</i> , 2007, 164, 500-508.	7.2	218
120	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 212-244.	2.6	136
121	Effects of substance P on memory and mood in healthy male subjects. <i>Human Psychopharmacology</i> , 2007, 22, 567-573.	1.5	16
122	Corpus callosum abnormalities in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 417-22.	2.4	35
123	Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFN $\alpha$ ): results from a prospective study. <i>European Psychiatry</i> , 2006, 21, 204-210.	0.2	58
124	Increased nocturnal interleukin-6 excretion in patients with primary insomnia: A pilot study. <i>Brain, Behavior, and Immunity</i> , 2006, 20, 246-253.	4.1	162
125	No response of plasma substance P, but delayed increase of interleukin-1 receptor antagonist to acute psychosocial stress. <i>Life Sciences</i> , 2006, 78, 3082-3089.	4.3	36
126	Gruppentherapiemodul zur Stärkung des Selbstwertes bei Patientinnen mit Borderline-Persönlichkeitsstörung. <i>Verhaltenstherapie</i> , 2006, 16, 212-221.	0.4	12



#	ARTICLE	IF	CITATIONS
127	Self-Stigma in Women With Borderline Personality Disorder and Women With Social Phobia. <i>Journal of Nervous and Mental Disease</i> , 2006, 194, 766-773.	1.0	128
128	Nocturnal Serum Leptin Values in Chronic Primary Insomnia: A Preliminary Report. <i>Nächtliche Leptin-Ausschüttung bei Primärer Insomnie: eine Pilotstudie. Somnologie</i> , 2006, 10, 192-199.	1.5	2
129	Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. <i>Brain Research</i> , 2006, 1102, 135-144.	2.2	27
130	Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production. <i>Journal of Neuroimmunology</i> , 2006, 174, 39-51.	2.3	41
131	Brief Reports: Self-Stigma, Empowerment, and Perceived Legitimacy of Discrimination Among Women With Mental Illness. <i>Psychiatric Services</i> , 2006, 57, 399-402.	2.0	132
132	Sleep in Adults with Attention-Deficit/Hyperactivity Disorder: a Controlled Polysomnographic Study Including Spectral Analysis of the Sleep EEG. <i>Sleep</i> , 2005, 28, 877-884.	1.1	90
133	Serotonin via 5-HT <sub>7</sub> receptors activates p38 mitogen-activated protein kinase and protein kinase C $\delta$ resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. <i>Journal of Neurochemistry</i> , 2005, 93, 549-559.	3.9	62
134	The 5-HT <sub>3</sub> receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. <i>Biochemical Pharmacology</i> , 2005, 70, 369-380.	4.4	83
135	Affective dysregulation and dissociative experience in female patients with borderline personality disorder: a startle response study. <i>Journal of Psychiatric Research</i> , 2005, 39, 85-92.	3.1	150
136	Increased delta power and discrepancies in objective and subjective sleep measurements in borderline personality disorder. <i>Journal of Psychiatric Research</i> , 2005, 39, 489-498.	3.1	65
137	Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. <i>Glia</i> , 2005, 51, 199-208.	4.9	126
138	Deep brain stimulation for treatment of refractory depression. <i>Lancet</i> , The, 2005, 366, 1420-1422.	13.7	106
139	No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. <i>European Neuropsychopharmacology</i> , 2005, 15, 641-646.	0.7	9
140	Substance P Receptor Antagonists in Psychiatry. <i>CNS Drugs</i> , 2005, 19, 275-293.	5.9	106
141	Effects of substance P and its antagonist L-733060 on long term potentiation in guinea pig hippocampal slices. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 315-319.	4.8	19
142	Substance P in serum and cerebrospinal fluid of depressed patients: No effect of antidepressant treatment. <i>Psychiatry Research</i> , 2005, 136, 1-6.	3.3	18
143	1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH. <i>Journal of Neurochemistry</i> , 2004, 91, 263-273.	3.9	26
144	Increased diurnal salivary cortisol in women with borderline personality disorder. <i>Journal of Psychiatric Research</i> , 2004, 38, 559-565.	3.1	109

#	ARTICLE	IF	CITATIONS
145	New developments in the neurobiology of borderline personality disorder. <i>Current Psychiatry Reports</i> , 2004, 6, 43-50.	4.5	60
146	Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor. <i>Journal of Neurochemistry</i> , 2004, 86, 69-76.	3.9	20
147	Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia. <i>Journal of Neurochemistry</i> , 2004, 86, 173-178.	3.9	38
148	Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. <i>Pain</i> , 2004, 110, 470-479.	4.2	139
149	Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. <i>Behaviour Research and Therapy</i> , 2004, 42, 487-499.	3.1	403
150	Borderline personality disorder. <i>Lancet, The</i> , 2004, 364, 453-461.	13.7	1,219
151	Neurokinin-1 Receptor Expression and Its Potential Effects on Tumor Growth in Human Pancreatic Cancer. <i>Laboratory Investigation</i> , 2003, 83, 731-742.	3.7	106
152	Frontolimbic brain abnormalities in patients with borderline personality disorder. <i>Biological Psychiatry</i> , 2003, 54, 163-171.	1.3	312
153	Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. <i>Neurochemistry International</i> , 2003, 42, 131-137.	3.8	87
154	Substance P and Substance P Receptor Antagonists in the Pathogenesis and Treatment of Affective Disorders. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 56-63.	2.6	38
155	Title is missing!. <i>Journal of Nervous and Mental Disease</i> , 2003, 191, 248-254.	1.0	15
156	Interferon alpha (IFN $\alpha$ ) and psychiatric syndromes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 731-746.	4.8	179
157	Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. <i>Journal of Neuroimmunology</i> , 2002, 132, 18-24.	2.3	88
158	Effects of the Neuropeptide Substance P on Sleep, Mood, and Neuroendocrine Measures in Healthy Young Men. <i>Neuropsychopharmacology</i> , 2002, 27, 1041-1049.	5.4	60
159	Transient total sleep loss in cerebral Whipple's disease: a longitudinal study. <i>Journal of Sleep Research</i> , 2002, 11, 321-329.	3.2	39
160	Interleukin-1 $\beta$ and Tumor Necrosis Factor- $\alpha$ Induce Expression of $\alpha$ 1-Antichymotrypsin in Human Astrocytoma Cells by Activation of Nuclear Factor- $\kappa$ B. <i>Journal of Neurochemistry</i> , 2002, 67, 2039-2044.	3.9	52
161	Increased Plasma Concentration of Maprotiline by Coadministration of Risperidone. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 92-94.	1.4	13
162	Borna disease virus "does it infect humans and cause psychiatric disorders?". <i>Journal of Clinical Virology</i> , 2001, 21, 119-127.	3.1	29

#	ARTICLE	IF	CITATIONS
163	Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. <i>Psychopharmacology</i> , 2000, 152, 383-389.	3.1	138
164	The Neuropeptide Substance P Activates p38 Mitogen-Activated Protein Kinase Resulting in IL-6 Expression Independently from NF- $\kappa$ B. <i>Journal of Immunology</i> , 2000, 165, 5606-5611.	0.8	125
165	Anti-inflammatory drugs: a hope for Alzheimer's disease?. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 671-683.	4.1	46
166	Sleep deprivation and growth-hormone secretion. <i>Lancet, The</i> , 2000, 356, 2096-2097.	13.7	7
167	Pain perception during self-reported distress and calmness in patients with borderline personality disorder and self-mutilating behavior. <i>Psychiatry Research</i> , 2000, 95, 251-260.	3.3	216
168	Strategies to delay the onset of Alzheimer's disease. <i>Exs</i> , 2000, 89, 211-225.	1.4	1
169	Borna Disease Virus in Human Brains with a Rare Form of Hippocampal Degeneration but Not in Brains of Patients with Common Neuropsychiatric Disorders. <i>Journal of Infectious Diseases</i> , 1999, 180, 1695-1699.	4.0	41
170	Insomnia for 5 years. <i>Lancet, The</i> , 1999, 354, 1966.	13.7	17
171	The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alphas-antichymotrypsin synthesis in astrocytes by preventing degradation of $\text{I}\kappa\text{B}$ -alpha. <i>Neuropharmacology</i> , 1999, 38, 1325-1333.	4.1	30
172	Substance P and Histamine Induce Interleukin-6 Expression in Human Astrocytoma Cells by a Mechanism Involving Protein Kinase C and Nuclear Factor- $\kappa$ B. <i>Journal of Neurochemistry</i> , 1998, 70, 1577-1583.	3.9	54
173	Expression and Regulation of Cyclooxygenase-2 in Rat Microglia. <i>FEBS Journal</i> , 1997, 243, 726-731.	0.2	220
174	Potent inhibition of interleukin-6 expression in a human astrocytoma cell line by tenidap. <i>Cell and Tissue Research</i> , 1997, 288, 251.	2.9	11
175	Prostaglandin E <sub>2</sub> Induces Interleukin-6 Synthesis in Human Astrocytoma Cells. <i>Journal of Neurochemistry</i> , 1997, 68, 704-709.	3.9	91
176	Preattentive information processing as measured by backward masking and texton detection tasks in adolescents at high genetic risk for schizophrenia. <i>Schizophrenia Research</i> , 1996, 21, 171-182.	2.0	30
177	Effects of NSAIDs on IL-1 $\beta$ -induced IL-6 mRNA and protein synthesis in human astrocytoma cells. <i>NeuroReport</i> , 1996, 7, 1209-1213.	1.2	32
178	Pre- and postnatal development of dopaminergic neuron numbers in the male and female mouse midbrain. <i>Developmental Brain Research</i> , 1996, 94, 37-43.	1.7	45
179	Cyclooxygenase-2 expression in rat microglia is induced by adenosine A <sub>2a</sub> -receptors. <i>Glia</i> , 1996, 18, 152-180.	4.9	199
180	Sex Differentiation of Rat Hippocampal GABAergic Neurons. <i>European Journal of Neuroscience</i> , 1996, 8, 1718-1724.	2.6	21

#	ARTICLE	IF	CITATIONS
181	Interleukin-1 $\beta$ Uses Common and Distinct Signaling Pathways for Induction of the Interleukin-6 and Tumor Necrosis Factor- $\alpha$ Genes in the Human Astrocytoma Cell Line U373. <i>Journal of Neurochemistry</i> , 1996, 66, 1496-1503.	3.9	64
182	IL-1 $\beta$ and TNF- $\alpha$ , but not IL-6, induce IL-1-antichymotrypsin expression in the human astrocytoma cell line U373 MG. <i>NeuroReport</i> , 1995, 6, 2283-2286.	1.2	26
183	Electroencephalographic coherence in acquired immune deficiency syndrome. <i>Psychiatry Research</i> , 1994, 54, 1-11.	3.3	9
184	Preattentive information processing in schizophrenia. <i>Schizophrenia Research</i> , 1994, 14, 47-56.	2.0	22